Axsome Therapeutics AXSM Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's operating lease liabilities (total)?
- Axsome Therapeutics (AXSM) reported operating lease liabilities (total) of $23.01M in Q1 2026.
- How has Axsome Therapeutics's operating lease liabilities (total) changed year-over-year?
- Axsome Therapeutics's operating lease liabilities (total) decreased by 5.5% year-over-year, from $24.36M to $23.01M.
- What is the long-term trend for Axsome Therapeutics's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Axsome Therapeutics's operating lease liabilities (total) has grown at a 67.3% compound annual growth rate (CAGR), from $1.8M to $23.62M.
- What does operating lease liabilities (total) mean?
- The total value of future payments for operating leases.
- How do you interpret operating lease liabilities (total)?
- An increase reflects expansion in physical footprint or longer-term lease commitments.
- How does operating lease liabilities (total) compare across companies?
- Standardized across all companies with significant real estate or equipment lease portfolios.